Literature DB >> 9888086

Posterior capsule opacification. Part 1: Experimental investigations.

O Nishi1.   

Abstract

Posterior capsule opacification (PCO) is the most frequent complication associated with decreased vision after cataract surgery. Previous methods of preventing PCO have not proven to be practical, effective, and safe for routine clinical procedure, but some novel concepts and methods have recently been developed. This 2-part review looks at clinical and experimental investigations of PCO, focusing on developments since 1992. Clinical aspects will be presented in a later issue. This paper addresses (1) in vitro models for PCO research; (2) pathophysiology and molecular biology of lens epithelial cells (LECs); (3) prevention of PCO. Of special interest are methods of culturing human LECs obtained by capsulotomy during cataract surgery, including those obtained with an intact capsular bag, to provide an in vitro model for investigating the pathophysiology of LECs; the effect of a sharp bend in the lens capsule that induces contact inhibition of migrating LECs; more specific inhibition of migrating LECs using an immunotoxin, b-FGF-saporin, or EDTA and RGD-peptides.

Entities:  

Mesh:

Year:  1999        PMID: 9888086     DOI: 10.1016/s0886-3350(99)80020-0

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  24 in total

1.  [Influence of intraocular lens material and design on the development of posterior capsule opacification].

Authors:  O Nishi
Journal:  Ophthalmologe       Date:  2005-06       Impact factor: 1.059

Review 2.  [New methods for the prevention of posterior capsule opacification].

Authors:  G U Auffarth; T M Rabsilber; A J Reuland
Journal:  Ophthalmologe       Date:  2005-06       Impact factor: 1.059

3.  Prospective, non-randomised, long term clinical evaluation of a foldable hydrophilic single piece intraocular lens: results of the Centerflex FDA study.

Authors:  K A Becker; M Martin; T M Rabsilber; B B Entz; A J Reuland; G U Auffarth
Journal:  Br J Ophthalmol       Date:  2006-05-10       Impact factor: 4.638

4.  Long-term results of sealed capsule irrigation using distilled water to prevent posterior capsule opacification: a prospective clinical randomised trial.

Authors:  Tanja M Rabsilber; Il-Joo Limberger; Andreas J Reuland; Mike P Holzer; Gerd U Auffarth
Journal:  Br J Ophthalmol       Date:  2007-01-03       Impact factor: 4.638

5.  [Posterior capsule opacification after phacoemulsification in patients with rheumatoid arthritis].

Authors:  Dusica Pahor; Bojan Gracner; Tomaz Gracner; Artur Pahor
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

6.  Incidence of postoperative posterior capsular opacification following treatment with diclofenac 0.1% and ketorolac 0.5% ophthalmic solutions: 3-year randomized, double-masked, prospective clinical investigation.

Authors:  A J Flach; B J Dolan
Journal:  Trans Am Ophthalmol Soc       Date:  2000

7.  EGF receptor inhibitor erlotinib as a potential pharmacological prophylaxis for posterior capsule opacification.

Authors:  C Wertheimer; R Liegl; M Kernt; W Mayer; D Docheva; A Kampik; K H Eibl-Lindner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-01-18       Impact factor: 3.117

8.  The effect of phosphorylated Akt inhibition on posterior capsule opacification in an ex vivo canine model.

Authors:  Heather L Chandler; Terah R Webb; Curtis A Barden; Mirunalni Thangavelu; Samuel K Kulp; Ching-Shih Chen; Carmen M H Colitz
Journal:  Mol Vis       Date:  2010-10-29       Impact factor: 2.367

9.  Prevention of lens epithelial cell growth in vitro using mibefradil-containing PLGA micro particles.

Authors:  Arne Weidmann; Sabine Kwittner; Ria Beck; Joachim Teller; Ludwig Jonas; J Barbara Nebe
Journal:  Open Ophthalmol J       Date:  2008-06-12

10.  Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition.

Authors:  Heather L Chandler; Curtis A Barden; Ping Lu; Donna F Kusewitt; Carmen M H Colitz
Journal:  Mol Vis       Date:  2007-04-30       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.